ScripAmid a sweeping tightening of securities regulatory policies since late 2023, there has been a dearth of initial public offerings for bioventures in the Chinese mainland. But Hong Kong has just welcom
ScripChina’s top securities regulator has confirmed a recent slowdown in the review of initial public offering applications to help stabilize the domestic stock market, making the go-public process for Chi
ScripA dearth of innovative drug developers seeking public listings on China’s Nasdaq-like STAR Market has made investors scratch their heads, as the bourse, hailed as the country’s only stock market open